Nomogram Based on CMTM6 Expression and Clinical Characteristics to Predict Postoperative Overall Survival in Patients with Hepatocellular Carcinoma

Overview

Journal Histol Histopathol

Specialties Anatomy & Histology
Pathology

Date 2023 Jun 27

PMID 37366540

Authors

Mengjie Dai

Tao Lan

Hui Chen

Xin Li

Zilong Zhao

Yingxue Jiang

Long Yang

Songxiang Wang

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this study was to investigate the expression of CMTM6 in HCC tissues and its prognostic value, and to try to develop a nomogram prognostic model based on CMTM6.

Methods: In this retrospective study, immunohistochemical (IHC) staining was performed in 178 patients who underwent radical hepatectomy in the same surgical team. R software was used to construct the nomogram model. The Bootstrap sampling method was used for internal validation.

Results: CMTM6 is significantly expressed in HCC tissues and is closely associated with decreased overall survival (OS). PVTT (HR = 6.2, 95% CI: 3.06 12.6, P<0.001), CMTM6 (HR=2.30, 95% CI: 1.27 4.0, P=0.006) and MVI (HR=10.8, 95% CI: 4.19-27.6, P<0.001) were independent predictors of OS. The nomogram combined with CMTM6, PVTT and MVI was more predictive than the traditional TNM scoring system, and the prediction effects of 1-year and 3-year OS were accurate.

Conclusions: The prognosis of a patient may be predicted using high levels of CMTM6 expression in HCC tissues, and the nomogram model including CMTM6 expression has the best predictive ability.

References

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Burr M, Sparbier C, Chan Y, Williamson J, Woods K, Beavis P . CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017; 549(7670):101-105. PMC: 5706633. DOI: 10.1038/nature23643. View

Cadier B, Bulsei J, Nahon P, Seror O, Laurent A, Rosa I . Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. Hepatology. 2017; 65(4):1237-1248. DOI: 10.1002/hep.28961. View

Cai W, Wang Z, Wei C, Wu M, Zheng W, Zhang H . Prognostic evaluation of NANOG and OCT4 expression for posttransplantation hepatocellular carcinoma recurrence. J Cell Biochem. 2018; 120(5):8419-8429. DOI: 10.1002/jcb.28128. View

Cai B, Hou X, Zhou X, Ye T, Fang G, Huang H . Use of a novel index, the A-index, and its associated nomogram to predict overall survival rates after resection of primary hepatocellular carcinoma. Clin Chim Acta. 2019; 500:34-41. DOI: 10.1016/j.cca.2019.10.001. View

Campbell C, Wang T, McNaughton A, Barnes E, Matthews P . Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. J Viral Hepat. 2020; 28(3):493-507. PMC: 8581992. DOI: 10.1111/jvh.13452. View

Chen J, Shi X, Luo T, Zhao Y, Ye J, Bai T . The correlations between hepatitis B virus infection and hepatocellular carcinoma with portal vein tumor thrombus or extrahepatic metastasis. Eur J Gastroenterol Hepatol. 2019; 32(3):373-377. DOI: 10.1097/MEG.0000000000001514. View

Cheng M, Zhu W, Li Q, Dai D, Hou Y . Anti-cancer efficacy of biotinylated chitosan nanoparticles in liver cancer. Oncotarget. 2017; 8(35):59068-59085. PMC: 5601715. DOI: 10.18632/oncotarget.19146. View

Du M, Chen L, Zhao J, Tian F, Zeng H, Tan Y . Microvascular invasion (MVI) is a poorer prognostic predictor for small hepatocellular carcinoma. BMC Cancer. 2014; 14:38. PMC: 3922738. DOI: 10.1186/1471-2407-14-38. View

10.

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

11.

Guan X, Zhang C, Zhao J, Sun G, Song Q, Jia W . CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. EBioMedicine. 2018; 35:233-243. PMC: 6156716. DOI: 10.1016/j.ebiom.2018.08.012. View

12.

Han W, Lou Y, Zhang Y, Chen Y, Li Y, Gu W . Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J. 2001; 357(Pt 1):127-35. PMC: 1221935. DOI: 10.1042/0264-6021:3570127. View

13.

Han W, Ding P, Xu M, Wang L, Rui M, Shi S . Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics. 2003; 81(6):609-17. DOI: 10.1016/s0888-7543(03)00095-8. View

14.

Huang C, Wang Y, Liu S, Ding G, Liu W, Zhou J . Quantitative proteomic analysis identified paraoxonase 1 as a novel serum biomarker for microvascular invasion in hepatocellular carcinoma. J Proteome Res. 2013; 12(4):1838-46. DOI: 10.1021/pr3011815. View

15.

Kerr K, Brown M, Zhu K, Janes H . Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use. J Clin Oncol. 2016; 34(21):2534-40. PMC: 4962736. DOI: 10.1200/JCO.2015.65.5654. View

16.

Kulik L, El-Serag H . Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2018; 156(2):477-491.e1. PMC: 6340716. DOI: 10.1053/j.gastro.2018.08.065. View

17.

Ruiter M, Kwee A, Naaktgeboren C, De Groot I, Evers I, Groenendaal F . External validation of prognostic models to predict risk of gestational diabetes mellitus in one Dutch cohort: prospective multicentre cohort study. BMJ. 2016; 354:i4338. DOI: 10.1136/bmj.i4338. View

18.

Li D, Kang J, Madoff D . Locally ablative therapies for primary and metastatic liver cancer. Expert Rev Anticancer Ther. 2014; 14(8):931-45. DOI: 10.1586/14737140.2014.911091. View

19.

Li L, Li B, Zhang M . HBV DNA levels impact the prognosis of hepatocellular carcinoma patients with microvascular invasion. Medicine (Baltimore). 2019; 98(27):e16308. PMC: 6635265. DOI: 10.1097/MD.0000000000016308. View

20.

Li X, Chen L, Gu C, Sun Q, Li J . CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients. PeerJ. 2020; 8:e9536. PMC: 7439957. DOI: 10.7717/peerj.9536. View